Literature DB >> 6370127

Pharmacokinetics of ceftazidime in patients with renal insufficiency.

L S Welage, R W Schultz, J J Schentag.   

Abstract

The pharmacokinetics of ceftazidime were studied in 14 adult volunteers with different degrees of renal function. The elimination of ceftazidime was totally dependent on renal excretion. The clearance of ceftazidime ranged from 7.5 to 145.1 ml/min and correlated with both renal ceftazidime clearance and creatinine clearance (ClCR). It is recommended that 0.5 to 2.0 g of ceftazidime be given in extended dosages, with intervals dependent on the renal function of the patient. Patients with a ClCR of greater than 50 ml/min should be given ceftazidime every 8 h, those with a ClCR of 30 to 50 ml/min should be given the drug every 12 h, those with a ClCR of 15 to 30 ml/min should be given the drug once a day, and individuals with a ClCR of less than 15 ml/min should be given the drug on a day, and individuals with a ClCR of less than 15 ml/min should be given the drug on a 36- to 48-h regimen.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370127      PMCID: PMC185474          DOI: 10.1128/AAC.25.2.201

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

2.  Resistance to beta-lactam antibiotics in Bacteroides species.

Authors:  C E Nord; B Olsson-Liljequist
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

Review 3.  The tetracyclines: prospects at the beginning of the 1980s.

Authors:  I Chopra; T G Howe; A H Linton; K B Linton; M H Richmond; D C Speller
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

4.  Transferable multiple antibiotic resistance in Haemophilus influenzae.

Authors:  V O Rotimi; D C Turk
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

  4 in total
  18 in total

1.  Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

Authors:  A D Kashuba; C H Ballow; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

2.  Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.

Authors:  Henri Merdjan; Manickam Rangaraju; Antoine Tarral
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

3.  Disposition of ceftazidime in surgical patients with intra-abdominal infection.

Authors:  K L Heim-Duthoy; M P Bubrick; D M Cocchetto; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

5.  Population pharmacokinetics of continuous infusion ceftazidime.

Authors:  B C Frame; B F Facca; D P Nicolau; S N Triesenberg
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

6.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  The β-Lactams Strike Back: Ceftazidime-Avibactam.

Authors:  Evan J Zasowski; Jeffrey M Rybak; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2015-08       Impact factor: 4.705

Review 8.  Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.

Authors:  Jianguo Li; Mark Lovern; Todd Riccobene; Timothy J Carrothers; Paul Newell; Shampa Das; Angela K Talley; Margaret Tawadrous
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

9.  Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.

Authors:  Duangchit Panomvana; Sam-Ang Kiatjaroensin; Danabhand Phiboonbanakit
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.